Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia:Augmentation of LAK-Cell Cytotoxicity by Combinations of Lymphokines or Cytokines

  • J. V. Teichmann
  • W. D. Ludwig
  • H. Seibt-Jung
  • E. Thiel
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)


Adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) or induction of cytotoxic mechanisms by IL-2 alone was shown to be a promising approach in cancer therapy [1–11]. Most of the available data come from experimental and clinical studies of solid tumors, while only little is known about the effect of LAK cells against human leukemia [12–14]. Leukemia patients have been reported to have a deficiency in natural killer (NK) cell functions which may contribute to leukemogenesis. Experimental data on correcting this deficiency by IL-2 make it possible that adoptive immunotherapy of leukemia patients may be of great value in the treatment of human leukemia [15, 16]. In the present study we investigated the ability of LAK cells to lyse fresh human leukemia cells in vitro and evaluated the augmentation of cytotoxic mechanisms by combined application of IL-2 and other lymphokines or cytokines and by inhibition of prostaglandin synthesis during the activation process.


Hairy Cell Leukemia Adoptive Immunotherapy Prolymphocytic Leukemia Fresh Leukemic Cell Fresh Human Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492PubMedCrossRefGoogle Scholar
  2. 2.
    Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma:phase I trial. Cancer Res 46:2101–2104PubMedGoogle Scholar
  3. 3.
    Lotze MT, Matory YL, Rayner AA, Etting¬hausen SE, Vetto JT, Seipp CA, RosenbergPubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897PubMedCrossRefGoogle Scholar
  5. 5.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion of recombinant in-terleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905PubMedCrossRefGoogle Scholar
  6. 6.
    Ingram M, Shelden CH, Jacques S, Skillen RG, Bradley WG, Techy GB, Freshwater DB, Abts RM, Rand RW (1987) Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489–498PubMedGoogle Scholar
  7. 7.
    Rosenberg SA (1988) Cancer therapy with interleukin-2:immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 6:403–405PubMedGoogle Scholar
  8. 8.
    Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclo-phosphamide and low-dose intravenous in-terleukin-2 in disseminated melanoma. J Clin Oncol 6:409–424PubMedGoogle Scholar
  9. 9.
    Sosman JA, Kohler PC, Hank J, Moor KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2:responses of renal carcinoma with acceptable toxicity. JNCI 80:60–63PubMedGoogle Scholar
  10. 10.
    Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 108:518–523PubMedGoogle Scholar
  11. 11.
    Gambacorti-Passerini C, Radrizzani M, Marolda R, Belli F, Sciorelli G, Galazka AR, Schindler JD, Cascinelli N, Parmiani G (1988) In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin-2. Int J Cancer 41:700–706PubMedCrossRefGoogle Scholar
  12. 12.
    Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938–948PubMedGoogle Scholar
  13. 13.
    Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727PubMedGoogle Scholar
  14. 14.
    Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R (1988) In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2:50–54PubMedGoogle Scholar
  15. 15.
    Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716PubMedGoogle Scholar
  16. 16.
    Lotzova E, Savary CA, Herberman RB, Dicke KA (1986) Can NK cells play a role in therapy of leukemia? Nat Immun Cell Growth Regul 5:61–63PubMedGoogle Scholar
  17. 17.
    Ludwig W-D, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H (1988) Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. Blood 71:1518–1528PubMedGoogle Scholar
  18. 18.
    Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K (1985) Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-gamma (IFN-03γ). J Immunol 134:3124–3129PubMedGoogle Scholar
  19. 19.
    Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes:effect of tumor necrosis factor-alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788–792PubMedGoogle Scholar
  20. 20.
    Scheurich P, Thoma B, Uecer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha:induction of TNF receptors on human T cells and TNF-alpha mediated enhancement of T cell responses. J Immunol 138:1786–1790PubMedGoogle Scholar
  21. 21.
    Nii A, Sone S, Utsugi T, Yanagawa H, Ogura T (1988) Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induc-tion by monocytes, depending on their functional state. Int J Cancer 41:33–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. V. Teichmann
    • 1
  • W. D. Ludwig
    • 1
  • H. Seibt-Jung
    • 1
  • E. Thiel
    • 1
  1. 1.Dept. of Hematology and Oncology, University-hospital SteglitzFree University of BerlinGermany

Personalised recommendations